Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M. Ohno S, et al. Among authors: iwata h. Breast Cancer Res Treat. 2013 Nov;142(1):69-80. doi: 10.1007/s10549-013-2691-y. Breast Cancer Res Treat. 2013. PMID: 24122389 Free PMC article. Clinical Trial.
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.
Takada M, Sugimoto M, Ohno S, Kuroi K, Sato N, Bando H, Masuda N, Iwata H, Kondo M, Sasano H, Chow LW, Inamoto T, Naito Y, Tomita M, Toi M. Takada M, et al. Among authors: iwata h. Breast Cancer Res Treat. 2012 Jul;134(2):661-70. doi: 10.1007/s10549-012-2109-2. Epub 2012 Jun 12. Breast Cancer Res Treat. 2012. PMID: 22689089
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Takada M, et al. Among authors: iwata h. Breast Cancer Res Treat. 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9. Epub 2014 Mar 30. Breast Cancer Res Treat. 2014. PMID: 24682674 Free article.
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.
Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Masuda N, et al. Among authors: iwata h. Breast Cancer. 2018 Jul;25(4):407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14. Breast Cancer. 2018. PMID: 29445928 Free PMC article. Clinical Trial.
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Kawaguchi K, Ishiguro H, Morita S, Nakamura S, Ohno S, Masuda N, Iwata H, Aogi K, Kuroi K, Toi M; Japan Breast Cancer Research Group (JBCRG). Kawaguchi K, et al. Among authors: iwata h. Breast Cancer Res Treat. 2011 Nov;130(2):627-34. doi: 10.1007/s10549-011-1641-9. Epub 2011 Jun 23. Breast Cancer Res Treat. 2011. PMID: 21698408 Free article.
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer.
Ohnoa S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F. Ohnoa S, et al. Among authors: iwata h. Biomed Pharmacother. 2005 Oct;59 Suppl 2:S323-4. doi: 10.1016/s0753-3322(05)80063-0. Biomed Pharmacother. 2005. PMID: 16507401
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Ohno S, et al. Among authors: iwata h. Ann Oncol. 2010 Dec;21(12):2342-2347. doi: 10.1093/annonc/mdq249. Epub 2010 May 21. Ann Oncol. 2010. PMID: 20494961 Free article. Clinical Trial.
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Toi M, et al. Among authors: iwata h. Br J Cancer. 2009 Nov 17;101(10):1676-82. doi: 10.1038/sj.bjc.6605343. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844234 Free PMC article. Clinical Trial.
3,039 results